News
Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...
The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...
Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...
NDTV Profit on MSN6d
Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug SectorCipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Opinion
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly LawsuitThis lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Zacks Investment Research on MSN2d
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback